These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23167665)

  • 1. Current update in the management of diabetic nephropathy.
    Van Buren PN; Toto R
    Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-fibrosis therapy and diabetic nephropathy.
    Karihaloo A
    Curr Diab Rep; 2012 Aug; 12(4):414-22. PubMed ID: 22644874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
    Cherney DZ; Perkins BA
    Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
    Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA
    Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving strategies for renoprotection: diabetic nephropathy.
    Parving HH; Hovind P; Rossing K; Andersen S
    Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):515-22. PubMed ID: 11458033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and old agents in the management of diabetic nephropathy.
    Lytvyn Y; Bjornstad P; Pun N; Cherney DZ
    Curr Opin Nephrol Hypertens; 2016 May; 25(3):232-9. PubMed ID: 26890303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of diabetic nephropathy: Recent progress and future perspective.
    Ahmad J
    Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
    Parving HH; Hovind P
    Curr Hypertens Rep; 2002 Oct; 4(5):387-93. PubMed ID: 12217258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin blockade in type 2 diabetic renal disease.
    Ruilope LM; Luño J
    Kidney Int Suppl; 2002 Dec; (82):S61-3. PubMed ID: 12410857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
    Johnson SA; Spurney RF
    Am J Physiol Renal Physiol; 2015 Nov; 309(10):F807-20. PubMed ID: 26336162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 17. [The role of ramipril in the therapy of diabetic nephropathy].
    Dézsi CA
    Orv Hetil; 2014 Feb; 155(7):263-9. PubMed ID: 24509355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease.
    Andersen NH; Mogensen CE
    Curr Hypertens Rep; 2004 Oct; 6(5):369-76. PubMed ID: 15341690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
    Zhang MZ; Wang S; Yang S; Yang H; Fan X; Takahashi T; Harris RC
    Am J Physiol Renal Physiol; 2012 Feb; 302(4):F433-8. PubMed ID: 22114203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.